Kosan BioSciences -- KOSN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kosan BioSciences -- KOSN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (21)	8/10/2001 3:27:37 PM
From: JOEBT1	Read Replies (1) of 933

Wilder--Talked to KOSN management recently. Apparently the first PR on the Epothilone D trial will be released after the first patient is dosed with the drug. There wouldn't be any preliminary PR's on IND filing. They have produced all the epo-d needed for Phase I and are working on Phase II.The J&J antibiotics are in pre-clinicals and going well. The royalties on the J&J drugs will range from the high single digits to low double digits. Not bad for a deal done in 1998. The work on Motilide (gastric reflux) and nerve regeneration is also underway. They feel that their intellectual property in polyketides is very strong and well protected. Joe

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next